Indoco Remedies Limited Stock

Equities

INDOCO

INE873D01024

Pharmaceuticals

Delayed NSE India S.E. 06:02:10 2024-07-03 am EDT 5-day change 1st Jan Change
344.8 INR +0.01% Intraday chart for Indoco Remedies Limited +5.67% -12.74%
Sales 2024 18.17B 218M Sales 2025 * 19.73B 236M Capitalization 31.78B 381M
Net income 2024 985M 11.8M Net income 2025 * 1.36B 16.25M EV / Sales 2024 1.67 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.61 x
P/E ratio 2024
31.3 x
P/E ratio 2025 *
23.4 x
Employees 6,000
Yield 2024
0.46%
Yield 2025 *
0.56%
Free-Float 34%
More Fundamentals * Assessed data
Dynamic Chart
Indoco Remedies Faces Potential GST Demand of INR 0.282 Million from Office of the Joint Commissioner State Tax Special Circle , Ranchi CI
Indoco Remedies Gets US FDA's Tentative Approval for Generic Type 2 Diabetes Drug MT
Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets CI
Indoco Remedies Gets Final Nod from US FDA for Pregabalin Capsules MT
Indoco Remedies Ltd. Receives Final ANDA Approval from USFDA for Pregabalin Capsules CI
Indoco Remedies Limited Receives Show Cause Notice from Office of the Joint Commissioner of State Tax Patna Special Circle, Patna Bihar CI
Indoco Remedies Gets Zero Observations from US FDA for Navi Mumbai, India Plant, IAS Division MT
Transcript : Indoco Remedies Limited, Q4 2024 Earnings Call, May 16, 2024
Indoco Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Indoco Remedies Limited Receives Show Cause Notice Received from the Goods and Service Tax Authority CI
Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024 CI
Indoco Remedies Arm Begins Commercial Production from New Manufacturing Unit MT
Indoco Remedies to Buy Land in Mumbai for Expansion MT
Indoco Remedies Arm Begins Commercial Production at New Oral Care Unit MT
Transcript : Indoco Remedies Limited, Q3 2024 Earnings Call, Jan 23, 2024
More news
1 day+0.01%
1 week+5.67%
Current month+6.17%
1 month+12.99%
3 months+0.47%
6 months-11.75%
Current year-12.74%
More quotes
1 week
319.40
Extreme 319.4
354.40
1 month
286.60
Extreme 286.6
354.40
Current year
286.60
Extreme 286.6
415.00
1 year
286.60
Extreme 286.6
415.00
3 years
286.60
Extreme 286.6
530.25
5 years
132.45
Extreme 132.45
530.25
10 years
132.45
Extreme 132.45
530.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 04-03-26
Director of Finance/CFO - 21-09-01
Chairman 85 63-07-01
Members of the board TitleAgeSince
Chairman 85 63-07-01
Director/Board Member 63 81-12-31
Chief Executive Officer 54 04-03-26
More insiders
Date Price Change Volume
24-07-03 344.8 +0.01% 224 996
24-07-02 344.8 +3.98% 491,502
24-07-01 331.6 +2.09% 123,750
24-06-28 324.8 +0.85% 47,210
24-06-27 322 -1.32% 53,156

Delayed Quote NSE India S.E., July 03, 2024 at 06:02 am EDT

More quotes
Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
344.8 INR
Average target price
356.4 INR
Spread / Average Target
+3.36%
Consensus
  1. Stock Market
  2. Equities
  3. INDOCO Stock